✦ LIBER ✦

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

✍ Scribed by Scott A. Halperin; Brian Ward; Curtis Cooper; Gerald Predy; Francisco Diaz-Mitoma; Marc Dionne; Joanne Embree; Allison McGeer; Paul Zickler; Karl-Heinz Moltz; René Martz; Ingo Meyer; Shelly McNeil; Joanne M. Langley; Eduardo Martins; William L. Heyward; J. Tyler Martin

Book ID: 116964758
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 344 KB
Volume: 30
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2012.01.087

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of different t

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults

✍ Scott A. Halperin; Shelly McNeil; Joanne M. Langley; Bruce Smith; Donna MacKinno 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 283 KB

Comparison of the safety and immunogenic

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

✍ Scott A. Halperin; Simon Dobson; Shelly McNeil; Joanne M. Langley; Bruce Smith; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Immunogenicity and safety of an investig

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

✍ Heyward, William L.; Kyle, Michael; Blumenau, Joseph; Davis, Matthew; Reisinger, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 517 KB

Immunogenicity and safety of a tetravale

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzaetype b conjugate vaccine in healthy children aged 12–23

✍ Fred Zepp; Ulrich Behre; Klaus Kindler; Karl-Heinz Laakmann; Heidemarie Pankow-C 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 166 KB